Skip to content

Member

Marina MESURE

The Left · France

Group
The Left
Country
France
Roll-call participation
97.1 %ⓘ of 620 roll calls in office · chamber median 90.6 % · whole term, final votes
With majority line
91.1 %ⓘ of 596 votes where the group had a line · The Left median 86.6 %
More facts (5)
National party
LFI La France Insoumise
In office
Since 16 Jul 2024
Against clear line
11 of 498 votesⓘ
Committees
INTA (substitute), ITRE, SEDE (substitute)
Member id
236053
More

Record

The member’s figures against the median of their group and of the chamber. Each vote counts the member in the group they belonged to that day.

Roll-call participation ⓘ

97.1 %

602 of 620 final votes while in office

The Left median: 86.9 % (+10.2 pts)

Chamber median: 90.6 %

With majority line ⓘ

91.1 %

543 of 596 votes where their group had a line

The Left median: 86.6 % (+4.5 pts)

Against clear line ⓘ

2.2 %

11 of 498 votes where their group had a clear line

6 opposite (for ↔ against), 4 abstained against the line, 1 voted for or against when the line was to abstain

Abstention ⓘ

14.1 %

85 of 602 votes cast

Participation 97.1 % — The Left median 86.9 %, 47 members.ⓘ
Data as a table
Participation among the 47 members of the The Left with enough votes.
FigureParticipation
Marina MESURE97.1 %
The Left median86.9 %
Lowest in the group37.7 %
Highest in the group99.4 %
Members47
With majority line 91.1 % — The Left median 86.6 %, 47 members.ⓘ
Data as a table
With majority line among the 47 members of the The Left with enough votes.
FigureWith majority line
Marina MESURE91.1 %
The Left median86.6 %
Lowest in the group64.5 %
Highest in the group91.8 %
Members47
  • Whole term, 620 final votes; 620 of 794 decisions had a final vote recorded by name. The dots are the other members of The Left; no ranks.
  • “No vote recorded” is not the same as absent: leave, illness and chairing the sitting look the same.
  • A group’s line is inferred from its members’ votes — Parliament publishes no whip.

Votes, 5 928

Export

Every roll-call vote of the term with the member’s position, newest first.

Result: for–against–abstained. Majority line: how most of the member’s group voted that day (“Tie” when no position won). ≠ group marks a vote otherwise than a clear line (at least two thirds, with at least 10 members voting) of their group.
DateDecision and voteResultPositionMajority line
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Final vote — text as a wholeAdopted 434 for, 49 against, 168 abstainedPosition: Abstained Majority line: Abstained
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Amendment 12, adding text after paragraph 12 72 for, 522 against, 51 abstainedPosition: Against Majority line: Against
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement Final vote on the draft Council decisionConsent given 473 for, 114 against, 58 abstainedPosition: Against Majority line: Against
9 Sept 2025EU-Brazil Agreement: cooperation with and through Europol and the Federal Police of Brazil Final vote on the draft Council decisionConsent given 606 for, 5 against, 19 abstainedPosition: Abstained Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Final votePassed 431 for, 145 against, 76 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 395 to recital 19 187 for, 442 against, 16 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 409 + 417 (voted as one) to Annex VII, Part C, point 16 208 for, 431 against, 7 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 371 to Annex VII, Part C, point 13 530 for, 112 against, 4 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 408 + 416 (voted as one) to Annex VII, Part C, point 6 204 for, 438 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 407 to Annex VII, Part C, point 4 137 for, 447 against, 61 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 318 to Article 55, après le paragraph 2 512 for, 120 against, 14 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 390 to Article 55, après le paragraph 2 105 for, 538 against, 3 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 389 to Article 38, paragraph 3, après le point b 96 for, 549 against, 3 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 388 to Article 18, paragraph 1 124 for, 515 against, 7 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 387 to Article 7, après le paragraph 4 207 for, 431 against, 10 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 2 451 for, 182 against, 10 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 1 461 for, 185 against, 5 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 394 to Article 6, paragraph 1, après l'alinéa 2 142 for, 496 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 403 to Article 6, paragraph 1, alinéa 2 192 for, 442 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 130 to Article 6, paragraph 1, alinéa 1 444 for, 189 against, 14 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 402 to Article 6, paragraph 1, alinéa 1 194 for, 434 against, 15 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 393 to Article 6, paragraph 1, alinéa 1 120 for, 529 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 2 438 for, 196 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 1 452 for, 195 against, 2 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 134 to Article 6 473 for, 154 against, 22 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 2 512 for, 122 against, 15 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 1 505 for, 126 against, 19 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 401 to Article 6 131 for, 447 against, 72 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 392 to Article 4, après le paragraph 1 138 for, 504 against, 4 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 391 to Article 4, paragraph 1, après le point b 138 for, 508 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 399 + 412 (voted as one) to Article 3, paragraph 1, point 15 168 for, 445 against, 36 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 398 to Article 3, paragraph 1, après le point 9 199 for, 437 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 397 to Article 3, paragraph 1, point 9 158 for, 471 against, 17 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 396 to Article 2, paragraph 6, partie introductive 197 for, 418 against, 30 abstainedPosition: Against Majority line: Against
8 Sept 2025Wednesday’s agenda – Request by the PPE Group Ordre du jour de mercredi — Demande du groupe PPE 384 for, 10 against, 51 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Final vote — text as a wholeAdopted 523 for, 75 against, 14 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 1 to paragraph 14 157 for, 428 against, 36 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 8, adding text after paragraph 13 95 for, 420 against, 119 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Paragraph 13 — part 2 483 for, 84 against, 67 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 7 to paragraph 13 80 for, 407 against, 151 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 6, adding text after paragraph 12 79 for, 531 against, 18 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 5 to paragraph 10 47 for, 560 against, 27 abstainedPosition: No vote recorded Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 4 to paragraph 8 88 for, 520 against, 22 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 3, adding text after paragraph 2 63 for, 552 against, 15 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 2, adding text after paragraph 1 123 for, 390 against, 110 abstainedPosition: For Majority line: For
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Final vote — text as a wholeAdopted 494 for, 83 against, 71 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 2, adding text after recital S 217 for, 409 against, 23 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 1, adding text after citation 2 226 for, 409 against, 17 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 34 — part 2 566 for, 60 against, 23 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 32 — part 1 588 for, 56 against, 7 abstainedPosition: No vote recorded Majority line: Against

Show all 50 votes on this page

Roll-call participation

One cell per sitting while in office, shaded by the share of that day’s roll calls the member voted in. The official attendance register is kept separately by Parliament.

No vote recorded on 1 of 80 sittings with roll calls.

"No vote recorded" is not the same as absent: leave, illness and chairing the sitting look the same.

Data as a table

Voting neighbours

Members who voted the same way most often in the roll calls they both took part in, within and outside the member’s group (group at the date of each vote), over all roll calls of the term.

At least 200 shared roll calls over at least six months in office together. Within = both sat in the same group on the date of the vote; a member who changed group can appear on both lists. Baseline = the median agreement of all pairs of members of the groups the two sat in on the date of each shared vote (within: the group they shared; outside: the two groups), weighted by the votes they shared in each combination.

Within The Left

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in the same group (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of that group.
SelectMemberGroupCountryAgreementBaseline
Emma FOURREAU The LeftFrance100 % of 5 248 shared87 %
Anthony SMITH The LeftFrance100 % of 5 309 shared87 %
Arash SAEIDI The LeftFrance100 % of 4 423 shared87 %
Leila CHAIBI The LeftFrance100 % of 5 588 shared87 %
Damien CARÊME The LeftFrance100 % of 4 914 shared87 %
Rima HASSAN The LeftFrance100 % of 4 416 shared87 %
Manon AUBRY The LeftFrance99 % of 5 578 shared87 %
Younous OMARJEE The LeftFrance95 % of 4 209 shared87 %
Mimmo LUCANO The LeftItaly93 % of 2 568 shared87 %
Martin GÜNTHER The LeftGermany93 % of 2 869 shared87 %

Show all 10 neighbours

Outside the group

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in different groups (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of the groups the two sat in on those votes (groups at the date, weighted by the votes shared in each combination).
SelectMemberGroupCountryAgreementBaseline
Ana MIRANDA PAZ GreensSpain87 % of 4 700 shared77 %
Vicent MARZÀ IBÁÑEZ GreensSpain86 % of 5 243 shared77 %
Benedetta SCUDERI GreensItaly85 % of 5 491 shared77 %
David CORMAND GreensFrance85 % of 5 595 shared77 %
Cristina GUARDA GreensItaly85 % of 4 804 shared77 %
Mélissa CAMARA GreensFrance84 % of 4 970 shared77 %
Saskia BRICMONT GreensBelgium84 % of 5 350 shared77 %
Leoluca ORLANDO GreensItaly84 % of 4 956 shared77 %
Marie TOUSSAINT GreensFrance84 % of 5 379 shared77 %
Jaume ASENS LLODRÀ GreensSpain84 % of 4 615 shared77 %

Show all 10 neighbours

Work

Seats in committees, delegations and intergroups, and the dossiers the member leads, shadows or negotiates.

Seats

Body: the committee, delegation or intergroup, with its kind. Role: the member’s role in it. From, To: the dates of the seat (“now” while it lasts).
BodyRoleFromTo
Committee on International TradeINTA CommitteeSubstitute19 Jul 2024now
Committee on Industry, Research and EnergyITRE CommitteeMember19 Jul 2024now
Committee on Security and DefenceSEDE CommitteeSubstitute23 Jan 2025now
Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN)DASE DelegationMember19 Sept 2024now
Delegation to the EU-Armenia Parliamentary Partnership Committee, the EU-Azerbaijan Parliamentary Cooperation Committee and the EU-Georgia Parliamentary Association CommitteeDSCA DelegationMember19 Sept 2024now
Intergroup on Fighting against PovertyIG10-12 Intergroup / working groupMember24 Jan 2025now
Intergroup on Trade UnionsIG10-24 Intergroup / working groupMember31 Jan 2025now
Subcommittee on Security and DefenceSEDE SubcommitteeSubstitute9 Dec 202419 Jan 2025
Delegation to the Euronest Parliamentary AssemblyDEPA Parliamentary assemblyMember19 Sept 20246 Oct 2024

Show all 9 seats

Dossiers

Dossier: the procedure the declaration names (“No dossier named” for a delegation without one). Role: rapporteur, shadow rapporteur, negotiator or delegation. Committee: the committee that appointed them. Date: of the declaration.
DossierRoleCommitteeDate
EU–Indonesia Comprehensive Economic Partnership AgreementShadow rapporteurINTA29 Sept 2026
European Union Space Services Agency and amending Regulation (EU) 2021/696Shadow rapporteurITRE21 Sept 2026
Establishing a framework of measures for the acceleration of industrial capacity and decarbonisation in strategic sectors and amending Regulations (EU) 2018/1724, (EU) 2024/1735 and (EU) 2024/3110Shadow rapporteurITRE2 Jun 2026
Establishing a framework of measures for the acceleration of industrial capacity and decarbonisation in strategic sectors and amending Regulations (EU) 2018/1724, (EU) 2024/1735 and (EU) 2024/3110Shadow rapporteurITRE20 May 2026
No dossier namedOfficial delegationINTA19 May 2026
No dossier namedOpinion rapporteurINTA11 May 2026
No dossier namedShadow rapporteur for an opinionINTA23 Apr 2026
Addressing the negative trade-related effects of global overcapacity on the Union steel marketShadow rapporteur for an opinionITRE18 Nov 2025
Global Gateway -– past impacts and future orientationShadow rapporteur for an opinionINTA2 Oct 2025
Safety, resilience and sustainability of space activities in the UnionShadow rapporteurITRE23 Sept 2025

Show all 17 dossier roles

Topics they work on (model-assigned)

Counts: dossiers they spoke on, led or amended, and their questions and motions.

In the chamber

Speeches and statements in plenary debates, newest first; the verbatim report is on Parliament’s site.

29 contributions recorded; 5 on behalf of their group; 38 minutes of speaking time.

Show all 29 recent contributions

Questions and motions, 60

Parliamentary questions and motions for resolutions the member authored or co-signed, newest first.

Date: tabled. Title: the question or motion, with its id. Kind: written question or motion for a resolution, with the number of co-authors. Answer: the date of the answer to a question.
DateTitleKindAnswer
7 Sept 2026Climate change, public health and the world of work: for a directive on maximum working temperatures O-10-2026-000035Oral questionwith 35 co-authorsNot yet answered
10 Aug 2026Contradiction of strengthening the trade partnership with Baku while Armenian hostages and prisoners continue to be detained in Azerbaijan E-10-2026-003248Written question17 Sept 2026
24 Jul 2026Azerbaijan’s erasure of Armenian cultural heritage from Nagorno-Karabakh E-10-2026-003121Written question21 Aug 2026
23 Jul 2026EU external relations and asserting the right of return of Armenians displaced from Nagorno-Karabakh E-10-2026-003106Written question2 Sept 2026
22 Jul 2026Crisis in the French lavender industry E-10-2026-003077Written question18 Sept 2026
22 Jul 2026Protecting workers against extreme heatwaves in the European Union E-10-2026-003076Written question21 Aug 2026
1 Jul 2026PROPOSAL FOR A DECISION requesting the Authority for European Political Parties and European Political Foundations to verify whether Europe of Sovereign Nations Party complies with the conditions laid down in Article 3(1), points (d) and (e), of Regulation (EU, Euratom) 2025/2445 B-10-2026-0338Motion for a resolutionwith 246 co-authors—
25 Jun 2026The recent coercive measures imposed by the United States against Cuba, their extraterritorial nature and the measures to be adopted to defend the interests of individuals and companies from EU countries O-10-2026-000029Oral questionwith 27 co-authorsNot yet answered
24 Jun 2026ECB’s decision to raise interest rates and its impact on the rising cost of living O-10-2026-000028Oral questionwith 39 co-authorsNot yet answered
17 Jun 2026Albania: defending ecosystems against Trump family mega-projects E-10-2026-002497Written questionwith 10 co-authors13 Aug 2026

Show all 60 questions and motions

Amendments tabled in committee, 46

Committee amendment documents that carry amendments by the member, with how many are theirs.

Date: of the amendment document. Text amended: the dossier and the document’s id. Committee: where the amendments were tabled. Amendments: how many in the document are the member’s.
DateText amendedCommitteeAmendments
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790936 CJ536
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790938 CJ535
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790937 CJ5312
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790005 CJ5319
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790932 CJ5311
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790933 CJ532
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790934 CJ5317
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790935 CJ5317
2 Jul 2026From prototypes to capabilities – enabling new defence actors to scale up SEDE-AM-789957 SEDE4
13 May 2026Establishing the Programme for agile and rapid defence innovation (AGILE) CJ55-AM-788873 CJ5517

Show all 46 amendment documents

Connections

Dossiers they lead or shadow, committees, party, delegation and other related pages.

Political groups this term

National delegation

  • Delegation France National delegation

Sources & citation

Where the facts on this page come from, and how to cite it.

Data source
Licensed CC BY 4.0.
Data version
data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1 · methods
Retrieved
2 October 2026

Cite as

EU Parl Watch Research (2026). “Marina MESURE”. Member record. memberId 236053. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/members/236053?page=77&scope=final&vscope=all (retrieved 2 October 2026). Official source: Member’s profile, European Parliament, https://www.europarl.europa.eu/meps/en/236053. Data: EP Open Data: member record, https://data.europarl.europa.eu/api/v2/meps/236053?format=application%2Fld%2Bjson (CC BY 4.0); data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1.
BibTeX
@misc{epw-member-236053,
  author = {{EU Parl Watch Research}},
  title = {{Marina MESURE}},
  year = {2026},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/members/236053?page=77&scope=final&vscope=all}},
  url = {https://news.eu-parl.st-solutions.dev/members/236053?page=77&scope=final&vscope=all},
  urldate = {2026-10-02},
  publisher = {EU Parl Watch Research},
  note = {Member record. memberId 236053. Official source: https://www.europarl.europa.eu/meps/en/236053. Data: EP Open Data: member record (CC BY 4.0); data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1}
}